1
|
Hequet O, Nosbaum A, Guironnet-Paquet A, Blasco E, Nicolas-Virelizier E, Griffith TS, Rigal D, Cognasse F, Nicolas JF, Vocanson M. CD8 + T cells mediate ultraviolet A-induced immunomodulation in a model of extracorporeal photochemotherapy. Eur J Immunol 2020; 50:725-735. [PMID: 32012249 DOI: 10.1002/eji.201948318] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2019] [Revised: 11/19/2019] [Accepted: 01/30/2020] [Indexed: 12/15/2022]
Abstract
Extracorporeal photochemotherapy (ECP) that takes advantage of the immunomodulatory effects of UV light has been extensively used for many years for the treatment of several T cell-mediated diseases, including graft-versus-host disease (GvHD) and systemic scleroderma. Immune mechanisms that lead to the establishment of T cell tolerance in ECP-treated patients remain poorly known. In this study, we have tested the effect of UV/psoralen-treated BM-derived dendritic cells, referred to as ECP-BMDCs on the outcome of an antigen-specific T cell-mediated reaction, that is, contact hypersensitivity (CHS), which is mediated by CD8+ effector T cells (CD8+ Teff ). The intravenous (i.v.) injection of antigen-pulsed ECP-BMDCs in recipient C57BL/6 mice induced specific CD8+ T cells endowed with immunomodulatory properties (referred to as CD8+ TECP ), which prevented the priming of CD8+ Teff and the development of CHS, independently of conventional CD4+ regulatory T cells. CD8+ TECP mediated tolerance by inhibiting the migration and functions of skin DC and subsequently the priming of CD8+ Teff . CD8+ TECP displayed none of the phenotypes of the usual CD8+ T regulatory cells described so far. Our results reveal an underestimated participation of CD8+ T cells to ECP-induced immunomodulation that could explain the therapeutic effects of ECP in T cell-mediated diseases.
Collapse
Affiliation(s)
- Olivier Hequet
- CIRI - Centre International de Recherche en Infectiologie, Team « Immunology of Skin Allergy and Vaccination », Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon University, F-69007, Lyon, France.,Etablissement Français du Sang (EFS) Auvergne Rhône-Alpes, Apheresis Unit, Hôpital Lyon Sud, Pierre Bénite, France.,Etablissement Français du Sang (EFS) Auvergne Rhône-Alpes, Scientific Departements, Saint-Etienne, France
| | - Audrey Nosbaum
- CIRI - Centre International de Recherche en Infectiologie, Team « Immunology of Skin Allergy and Vaccination », Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon University, F-69007, Lyon, France
| | - Aurélie Guironnet-Paquet
- CIRI - Centre International de Recherche en Infectiologie, Team « Immunology of Skin Allergy and Vaccination », Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon University, F-69007, Lyon, France
| | - Elisabeth Blasco
- CIRI - Centre International de Recherche en Infectiologie, Team « Immunology of Skin Allergy and Vaccination », Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon University, F-69007, Lyon, France
| | - Emmanuelle Nicolas-Virelizier
- CIRI - Centre International de Recherche en Infectiologie, Team « Immunology of Skin Allergy and Vaccination », Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon University, F-69007, Lyon, France
| | - Thomas S Griffith
- Department of Urology, Center for Immunology, University of Minnesota, Minneapolis, MN, USA
| | - Dominique Rigal
- Etablissement Français du Sang (EFS) Auvergne Rhône-Alpes, Scientific Departements, Saint-Etienne, France
| | - Fabrice Cognasse
- Etablissement Français du Sang (EFS) Auvergne Rhône-Alpes, Scientific Departements, Saint-Etienne, France.,GIMAP-EA 3064, Lyon University, Saint-Etienne, France
| | - Jean-François Nicolas
- CIRI - Centre International de Recherche en Infectiologie, Team « Immunology of Skin Allergy and Vaccination », Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon University, F-69007, Lyon, France
| | - Marc Vocanson
- CIRI - Centre International de Recherche en Infectiologie, Team « Immunology of Skin Allergy and Vaccination », Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon University, F-69007, Lyon, France
| |
Collapse
|
2
|
Chiambaretta F, Garraffo R, Elena P, Pouliquen P, Delval L, Rigal D, Dubray C, Goldschmidt P, Tabbara K, Cochereau I. Tear Concentrations of Azithromycin following Topical Administration of a Single Dose of Azithromycin 0.5%, 1.0%, and 1.5% Eyedrops (T1225) in Healthy Volunteers. Eur J Ophthalmol 2018; 18:13-20. [DOI: 10.1177/112067210801800103] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Purpose To evaluate azithromycin tear concentrations after one drop of T1225 0.5%, 1.0%, and 1.5% eyedrops. Methods In this randomized, double-masked study, 91 healthy volunteers received one drop into each eye of T1225 0.5% (n=23), T1225 1.0% (n=38), or T1225 1.5% (n=38). Azithromycin tear concentrations were measured by HPLC-MS at seven time points for 24 hours. Tolerability was evaluated. Results T1225 1.0% and 1.5% had similar pharmacokinetic profiles. After a post-instillation peak (167 to 178 mg/L after 10 minutes), mean concentrations remained above 7 mg/L for 24 hours (except for T1225 1% at H24). A delayed increase of the azithromycin mean tear concentration might be explained by the known late azithromycin release from tissues after storage in cells. Areas under inhibitory curve (AUICs) of T1225 1.0% and 1.5% were higher than AUICs of T1225 0.5% and ranged between 47 and 90. The three T1225 concentrations were safe for the ocular surface. Conclusions Once daily instillation of T1225 1.0% and 1.5% was shown to reach an AUIC markedly above the required threshold for an antibacterial activity against Gram-positive bacteria (25–35). These results suggest that a BID instillation is more likely to ensure antimicrobial activity against Gram-negative bacteria (threshold >100).
Collapse
Affiliation(s)
- F. Chiambaretta
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - R. Garraffo
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - P.P. Elena
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - P. Pouliquen
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - L. Delval
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - D. Rigal
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - C. Dubray
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - P. Goldschmidt
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - K. Tabbara
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| | - I. Cochereau
- Centre de Pharmacologie Clinique, Bâtiment du Centre de Recherche en Nutrition Humaine, Clermont-Ferrand - France
| |
Collapse
|
3
|
Pérès E, Bagdassarian E, This S, Villaudy J, Rigal D, Gazzolo L, Duc Dodon M. From Immunodeficiency to Humanization: The Contribution of Mouse Models to Explore HTLV-1 Leukemogenesis. Viruses 2015; 7:6371-86. [PMID: 26690200 PMCID: PMC4690867 DOI: 10.3390/v7122944] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Revised: 11/16/2015] [Accepted: 11/30/2015] [Indexed: 12/12/2022] Open
Abstract
The first discovered human retrovirus, Human T-Lymphotropic Virus type 1 (HTLV-1), is responsible for an aggressive form of T cell leukemia/lymphoma. Mouse models recapitulating the leukemogenesis process have been helpful for understanding the mechanisms underlying the pathogenesis of this retroviral-induced disease. This review will focus on the recent advances in the generation of immunodeficient and human hemato-lymphoid system mice with a particular emphasis on the development of mouse models for HTLV-1-mediated pathogenesis, their present limitations and the challenges yet to be addressed.
Collapse
Affiliation(s)
- Eléonore Pérès
- Laboratoire de Biologie Moléculaire de la Cellule, Unité Mixte de Recherche 5239, Centre National de la Recherche Scientifique, Ecole Normale Supérieure de Lyon, 69364 Lyon Cedex 7, France.
- SFR UMS3444 BioSciences Lyon-Gerland-Lyon Sud (UMS3444), 69366 Lyon Cedex 7, France.
| | - Eugénie Bagdassarian
- Laboratoire de Biologie Moléculaire de la Cellule, Unité Mixte de Recherche 5239, Centre National de la Recherche Scientifique, Ecole Normale Supérieure de Lyon, 69364 Lyon Cedex 7, France.
- SFR UMS3444 BioSciences Lyon-Gerland-Lyon Sud (UMS3444), 69366 Lyon Cedex 7, France.
- Master BioSciences, Département de Biologie, ENS Lyon, 69366 Lyon Cedex 7, France.
| | - Sébastien This
- Laboratoire de Biologie Moléculaire de la Cellule, Unité Mixte de Recherche 5239, Centre National de la Recherche Scientifique, Ecole Normale Supérieure de Lyon, 69364 Lyon Cedex 7, France.
- SFR UMS3444 BioSciences Lyon-Gerland-Lyon Sud (UMS3444), 69366 Lyon Cedex 7, France.
- Master BioSciences, Département de Biologie, ENS Lyon, 69366 Lyon Cedex 7, France.
| | - Julien Villaudy
- AIMM Therapeutics, Meibergdreef 59, 1105 BA Amsterdam Zuidoost, The Netherlands.
- Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 BA Amsterdam Zuidoost, The Netherlands.
| | | | - Louis Gazzolo
- Laboratoire de Biologie Moléculaire de la Cellule, Unité Mixte de Recherche 5239, Centre National de la Recherche Scientifique, Ecole Normale Supérieure de Lyon, 69364 Lyon Cedex 7, France.
- SFR UMS3444 BioSciences Lyon-Gerland-Lyon Sud (UMS3444), 69366 Lyon Cedex 7, France.
| | - Madeleine Duc Dodon
- Laboratoire de Biologie Moléculaire de la Cellule, Unité Mixte de Recherche 5239, Centre National de la Recherche Scientifique, Ecole Normale Supérieure de Lyon, 69364 Lyon Cedex 7, France.
- SFR UMS3444 BioSciences Lyon-Gerland-Lyon Sud (UMS3444), 69366 Lyon Cedex 7, France.
| |
Collapse
|
4
|
Moncharmont P, Makowski C, Dubois C, Rigal D. Traitement immunomodulateur dans l’allo-immunisation fœto-maternelle par anticorps anti-plaquettes anti-HPA-5b : à propos d’un cas sévère. Transfus Clin Biol 2015. [DOI: 10.1016/j.tracli.2015.06.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Chong W, Turro E, Metcalfe P, Yusuf R, Mérieux Y, Rigal D, Porcelijn L, Huiskes E, Lucas G, Bendukidze N, Green A, Fontão-Wendel R, Husebekk A, Dixey J, Guest A, Mushens R, Ouwehand WH, Navarrete CV. A multicenter validation of recombinant β3 integrin-coupled beads to detect human platelet antigen-1 alloantibodies in 498 cases of fetomaternal alloimmune thrombocytopenia. Transfusion 2015; 55:2742-51. [DOI: 10.1111/trf.13222] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Revised: 03/23/2015] [Accepted: 05/11/2015] [Indexed: 11/29/2022]
Affiliation(s)
- Winnie Chong
- Histocompatibility and Immunogenetics Laboratories; National Health Service Blood and Transplant (NHSBT); Colindale, London UK
| | - Ernest Turro
- Department of Haematology; University of Cambridge and NHSBT Cambridge, Cambridge Biomedical Campus
- Medical Research Council Biostatistics Unit; Cambridge Biomedical Campus; Cambridge UK
| | - Paul Metcalfe
- National Institute for Biological Standards and Control Medicines and Healthcare Products Regulatory Agency; Potters Bar UK
| | - Rizwan Yusuf
- National Institute for Biological Standards and Control Medicines and Healthcare Products Regulatory Agency; Potters Bar UK
| | - Yves Mérieux
- Etablissement Français du Sang Rhône-Alpes (EFS); Lyon France
| | - Dominique Rigal
- Etablissement Français du Sang Rhône-Alpes (EFS); Lyon France
| | - Leendert Porcelijn
- Platelet and Leukocyte Serology Department; Sanquin Diagnostic Services; Amsterdam the Netherlands
| | - Elly Huiskes
- Platelet and Leukocyte Serology Department; Sanquin Diagnostic Services; Amsterdam the Netherlands
| | - Geoff Lucas
- Histocompatibility and Immunogenetics Laboratories; National Health Service Blood and Transplant (NHSBT); Filton, Bristol UK
| | - Nina Bendukidze
- Histocompatibility and Immunogenetics Laboratories; National Health Service Blood and Transplant (NHSBT); Filton, Bristol UK
| | - Ann Green
- Histocompatibility and Immunogenetics Laboratories; National Health Service Blood and Transplant (NHSBT); Filton, Bristol UK
| | | | | | - Jonathan Dixey
- International Blood Group Reference Laboratory (IBGRL); Filton Bristol UK
| | - Alan Guest
- International Blood Group Reference Laboratory (IBGRL); Filton Bristol UK
| | - Rosey Mushens
- International Blood Group Reference Laboratory (IBGRL); Filton Bristol UK
| | - Willem H. Ouwehand
- Department of Haematology; University of Cambridge and NHSBT Cambridge, Cambridge Biomedical Campus
| | - Cristina V. Navarrete
- Histocompatibility and Immunogenetics Laboratories; National Health Service Blood and Transplant (NHSBT); Colindale, London UK
- Division of Infection and Immunity; University College London; London UK
| |
Collapse
|
6
|
Fattoum J, Cannas G, Malki K, Dubost M, Rigal D, Michallet M. Intérêt de la transfusion de granulocytes dans les infections sévères chez des immunodéprimés suivis pour une hémopathie : expérience du service d’hématologie des Hospices Civils de Lyon sur une période de 5ans. Transfus Clin Biol 2014. [DOI: 10.1016/j.tracli.2014.08.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
7
|
Gilbert M, Paul S, Perrat G, Giannoli C, Pouteil Noble C, Morelon E, Rigal D, Dubois V. Impact of pretransplant human leukocyte antigen-C and -DP antibodies on kidney graft outcome. Transplant Proc 2014; 43:3412-4. [PMID: 22099809 DOI: 10.1016/j.transproceed.2011.09.023] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The aim of our study was to determine whether the presence of specific human leukocyte antigen (HLA)-C and -DP antibodies before transplantation influenced graft outcomes in immunized recipients. Two groups of pretransplant immunized recipients were studied: patients with only classical HLA-A, -B, -DR, -DQ antibodies (n = 176) and those with classical plus HLA-C and/or -DP antibodies (n = 27). Acute antibody-mediated rejection was preferentially associated with the presence of pretransplant anti-HLA-C and -DP antibodies (5/6 cases). In four cases, acute rejection episodes were followed by graft loss within 15 months after transplantation. There was a significant increase in the number of acute rejection episodes especially antibody-mediated acute rejections (P = .036) and in the number of graft losses for immunologic reasons (P < .001) among the group with pretransplant anti-C and -DP antibodies. Pretransplant anti-DP antibodies seemed to be involved more frequently in poor graft outcomes as shown in several recent published cases. We need to investigate their specific role among a larger cohort, taking into account an epitope analysis.
Collapse
Affiliation(s)
- M Gilbert
- Histocompatibility Laboratory, Etablissement Français du Sang Rhône-Alpes, Lyon, France
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Moncharmont P, Rigal D. [Association of red blood cell and platelet allo-antibodies in platelet alloimmunized patients]. Transfus Clin Biol 2014; 21:99-102. [PMID: 24948207 DOI: 10.1016/j.tracli.2014.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2014] [Accepted: 05/14/2014] [Indexed: 10/25/2022]
Abstract
PURPOSE OF THE STUDY Use of matched red blood cell (RBC) concentrates is imperative in patients with RBC allo-antibodies (Abs) and when platelet (PLT) specific allo-Abs are present additional difficulties occur for PLT transfusions. In order to evaluate the prevalence of the PLT and RBC allo-Abs association, a study on patients with PLT specific allo-Acs was performed. This association is not a rare event. PATIENTS AND METHODS In the database of a PLT immunohaematology laboratory, patients with PLT specific allo-Abs were selected and the presence and specificity of RBC allo-Abs was evaluated. RESULTS Six hundred and eighty seven patients (673 females, 14 males) with PLT specific allo-Abs were found. Six hundred and seventy-five patients (98.3%) had PLT specific allo-Abs with only one specificity. Anti-HPA-5b was the most frequent (539 cases). Twenty-nine (4.2%) patients had also RBC allo-Abs, including 27 females (93.1%) and two males. Seventy (58.6%) had RBC allo-Abs with only one specificity, 10 several and two unknown. Among the first, RBC allo-Abs directed against Rhesus blood group antigens were predominant (11 cases [64.7%]). Among the 29 patients with associated PLT and RBC allo-Abs, 15 (51.7%) were 50 or more years old and 14 (48.3%) under 50. CONCLUSION In PLT specific alloimmunized patients, detection of RBC alloimmunization is not a rare event. When RBC and PLT transfusions are required, the supply of matched RBC and PLT concentrates is more difficult.
Collapse
Affiliation(s)
- P Moncharmont
- Laboratoire d'immunologie plaquettaire, Établissement français du sang Rhône-Alpes, site de Lyon Gerland, 1-3, rue du Vercors, 69364 Lyon cedex 07, France.
| | - D Rigal
- Laboratoire d'immunologie plaquettaire, Établissement français du sang Rhône-Alpes, site de Lyon Gerland, 1-3, rue du Vercors, 69364 Lyon cedex 07, France
| |
Collapse
|
9
|
Paris S, Rigal D, Barlet V, Verdier M, Coudurier N, Bailly P, Brès JC. Flexible automated platform for blood group genotyping on DNA microarrays. J Mol Diagn 2014; 16:335-42. [PMID: 24726279 DOI: 10.1016/j.jmoldx.2014.02.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2013] [Revised: 02/06/2014] [Accepted: 02/12/2014] [Indexed: 11/17/2022] Open
Abstract
The poor suitability of standard hemagglutination-based assay techniques for large-scale automated screening of red blood cell antigens severely limits the ability of blood banks to supply extensively phenotype-matched blood. With better understanding of the molecular basis of blood antigens, it is now possible to predict blood group phenotype by identifying single-nucleotide polymorphisms in genomic DNA. Development of DNA-typing assays for antigen screening in blood donation qualification laboratories promises to enable blood banks to provide optimally matched donations. We have designed an automated genotyping system using 96-well DNA microarrays for blood donation screening and a first panel of eight single-nucleotide polymorphisms to identify 16 alleles in four blood group systems (KEL, KIDD, DUFFY, and MNS). Our aim was to evaluate this system on 960 blood donor samples with known phenotype. Study data revealed a high concordance rate (99.92%; 95% CI, 99.77%-99.97%) between predicted and serologic phenotypes. These findings demonstrate that our assay using a simple protocol allows accurate, relatively low-cost phenotype prediction at the DNA level. This system could easily be configured with other blood group markers for identification of donors with rare blood types or blood units for IH panels or antigens from other systems.
Collapse
Affiliation(s)
- Sandra Paris
- Établissement Français du Sang Rhône Alpes, Lyon, France
| | | | - Valérie Barlet
- Établissement Français du Sang Rhône Alpes, Lyon, France
| | | | | | - Pascal Bailly
- Établissement Français du Sang Alpes Méditerranée, Marseille, France
| | - Jean-Charles Brès
- Établissement Français du Sang Rhône Alpes, Lyon, France; Établissement Français du Sang Pyrénées Méditerranée, Montpellier, France.
| |
Collapse
|
10
|
Guinchard E, Bricca P, Monnier S, Rigal D. [Non-invasive fetal RHD genotyping: Validation of the method with 200 patients]. Transfus Clin Biol 2014; 21:1-14. [PMID: 24559796 DOI: 10.1016/j.tracli.2013.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2012] [Accepted: 12/09/2013] [Indexed: 10/25/2022]
Abstract
BACKGROUND Non-invasive fetal RHD genotyping is an important tool to assess the risk of fetuse's hemolytic disease of anti-D allo-immunized pregnant woman by non-invasive method. A method of genotyping has been developed in the laboratory of Lyon-GHE according to Minon's team (J Gynecol Obstet Biol Reprod 2005): exon 4, 5, and 10 are amplified by real time PCR. At first, genotyping results of 200 pregnant women have been compared with RH1 phenotype at birth. The most important parameters of validation have been tested: the sensibility and the specificity; the negative predictive value; the correlation study permitted to define criteria of biological interpretation. The validation of this method permitted to determine critical points and the limits of the method due to the minor amount of fetal DNA in the maternal plasma and existence of many variant forms of the RHD gene. CONCLUSION We worked too in the perspective to the accreditation for our genetic laboratory.
Collapse
Affiliation(s)
- E Guinchard
- EFS Rhône-Alpes, site de Lyon-GHE, 28, rue Doyen-Lepine, 69677 Bron cedex, France.
| | - P Bricca
- EFS Rhône-Alpes, site de Lyon-GHE, 28, rue Doyen-Lepine, 69677 Bron cedex, France
| | - S Monnier
- EFS Rhône-Alpes, site de Lyon-GHE, 28, rue Doyen-Lepine, 69677 Bron cedex, France
| | - D Rigal
- EFS Rhône-Alpes, site de Lyon-Gerland, 1, rue du Vercors, 69007 Lyon, France
| |
Collapse
|
11
|
Hequet O, Le QH, Rodriguez J, Dubost P, Revesz D, Clerc A, Rigal D, Salles G, Coiffier B. Development of model for analysing respective collections of intended hematopoietic stem cells and harvests of unintended mature cells in apheresis for autologous hematopoietic stem cell collection. Transfus Apher Sci 2014; 50:294-302. [PMID: 24462181 DOI: 10.1016/j.transci.2013.12.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Revised: 12/09/2013] [Accepted: 12/17/2013] [Indexed: 11/29/2022]
Abstract
Hematopoietic stem cells (HSCs) required to perform peripheral hematopoietic autologous stem cell transplantation (APBSCT) can be collected by processing several blood volumes (BVs) in leukapheresis sessions. However, this may cause granulocyte harvest in graft and decrease in patient's platelet blood level. Both consequences may induce disturbances in patient. One apheresis team's current purpose is to improve HSC collection by increasing HSC collection and prevent increase in granulocyte and platelet harvests. Before improving HSC collection it seemed important to know more about the way to harvest these types of cells. The purpose of our study was to develop a simple model for analysing respective collections of intended CD34+ cells among HSC (designated here as HSC) and harvests of unintended platelets or granulocytes among mature cells (designated here as mature cells) considering the number of BVs processed and factors likely to influence cell collection or harvest. For this, we processed 1, 2 and 3 BVs in 59 leukapheresis sessions and analysed corresponding collections and harvests with a referent device (COBE Spectra). First we analysed the amounts of HSC collected and mature cells harvested and second the evolution of the respective shares of HSC and mature cells collected or harvested throughout the BV processes. HSC collections and mature cell harvests increased globally (p<0.0001) and their respective shares remained stable throughout the BV processes (p non-significant). We analysed the role of intrinsic (patient's features) and extrinsic (features before starting leukapheresis sessions) factors in collections and harvests, which showed that only pre-leukapheresis blood levels (CD34+cells and platelets) influenced both cell collections and harvests (CD34+cells and platelets) (p<0.001) and shares of HSC collections and mature unintended cells harvests (p<0.001) throughout the BV processes. Altogether, our results suggested that the main factors likely to influence intended HSC collections or unintended mature cell harvests were pre-leukapheresis blood cell levels. Our model was meant to assist apheresis teams in analysing shares of HSC collected and mature cells harvested with new devices or with new types of HSC mobilization.
Collapse
Affiliation(s)
- O Hequet
- Etablissement Français du Sang Rhône Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Benite, France; Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France.
| | - Q H Le
- Hospices Civils de Lyon, Department of Biostatistics, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - J Rodriguez
- Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France
| | - P Dubost
- Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France
| | - D Revesz
- Etablissement Français du Sang Rhône Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Benite, France
| | - A Clerc
- Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France
| | - D Rigal
- Etablissement Français du Sang Rhône Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Benite, France; Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France
| | - G Salles
- Hospices Civils de Lyon, Hematological unit, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - B Coiffier
- Hospices Civils de Lyon, Hematological unit, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| |
Collapse
|
12
|
Paris S, Silvy M, Bailly P, Verdier M, Barlet V, Rigal D, Brès JC. Développement d’une plate-forme automatisée de génotypage érythrocytaire étendu pour les donneurs de sang. Transfus Clin Biol 2013. [DOI: 10.1016/j.tracli.2013.03.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
13
|
Paris S, Dupont M, Silvy M, Bailly P, Rigal D, Brès JC. Bilan d’activité après deux années d’utilisation d’une puce à ADN dédiée au génotypage érythrocytaire étendu des patients. Transfus Clin Biol 2013. [DOI: 10.1016/j.tracli.2013.03.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
14
|
Boccoz S, Brès J, Bailly P, Rigal D, Blum L, Marquette C. Validation d’une plateforme totalement automatisée pour le génotypage érythrocytaire étendu. Transfus Clin Biol 2013. [DOI: 10.1016/j.tracli.2013.04.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Paris S, Bertrand G, Kaplan C, Rigal D, Brès JC. Développement de puces à ADN pour le génotypage des antigènes plaquettaires humains HPA-1, -5 et -15. Transfus Clin Biol 2013. [DOI: 10.1016/j.tracli.2013.03.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
16
|
Moncharmont P, Makowski C, Equy V, Andrini P, Rigal D. Occurrence of anti-HPA-5b alloantibodies during intravenous immunoglobulin treatment in an HPA-15b alloimmunised woman: a case report. Transfus Med 2013; 23:202-3. [PMID: 23402651 DOI: 10.1111/tme.12015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2012] [Revised: 10/29/2012] [Accepted: 01/17/2013] [Indexed: 11/27/2022]
|
17
|
Eljaafari A, Yuruker O, Ferrand C, Farre A, Addey C, Tartelin ML, Thomas X, Tiberghien P, Simpson E, Rigal D, Scott D. Isolation of Human CD4/CD8 Double-Positive, Graft-Versus-Host Disease–Protective, Minor Histocompatibility Antigen–Specific Regulatory T Cells and of a Novel HLA-DR7–Restricted HY-Specific CD4 Clone. J I 2012; 190:184-94. [DOI: 10.4049/jimmunol.1201163] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
18
|
Moncharmont P, Rigal D. Prévalence des anticorps antiplaquettes spécifiques chez les receveurs de concentrés plaquettaires avec effet indésirable transfusionnel. Transfus Clin Biol 2012; 19:333-7. [DOI: 10.1016/j.tracli.2012.06.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2012] [Accepted: 06/16/2012] [Indexed: 10/27/2022]
|
19
|
Cachat A, Villaudy J, Rigal D, Gazzolo L, Duc Dodon M. [Mice are not Men and yet… how humanized mice inform us about human infectious diseases]. Med Sci (Paris) 2012; 28:63-8. [PMID: 22289832 DOI: 10.1051/medsci/2012281018] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
The study of human pathologies is often limited by the absence of animal models which are robust, cost-effective and reproduce the hallmarks of human infections. While mice have been frequently employed to study human diseases, many of important pathogens display unique human tropism. These last two decades the graft of human progenitor cells or tissues into -immunodeficient mice has allowed the elaboration of so called humanized mice. Humanized mouse technology has made rapid progress, and it is now possible to achieve high levels of human chimerism in various organs and tissues, particularly the immune system and the liver. The review briefly summarizes the different models of humanized mice available for in vivo experiments. With a focus on lymphotropic, monocytotropic and hepatotropic viruses, we here discuss the current status and future prospects of these models for studying the pathogenesis of infectious diseases. Furthermore, they provide a powerful tool for the development of innovative therapies.
Collapse
Affiliation(s)
- Anne Cachat
- Virologie humaine, INSERM-U758, École Normale Supérieure, France
| | | | | | | | | |
Collapse
|
20
|
Thibaut J, Mérieux Y, Rigal D, Gillet G. A novel assay for the detection of anti-human platelet antigen antibodies (HPA-1a) based on peptide aptamer technology. Haematologica 2011; 97:696-704. [PMID: 22133781 DOI: 10.3324/haematol.2011.051276] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Neonatal alloimmune thrombocytopenia is mostly due to the presence of maternal antibodies against the fetal platelet antigen HPA-1a on the platelet integrin GPIIb-IIIa. Accurate detection of anti-HPA-1a antibodies in the mother is, therefore, critical. Current diagnostic assays rely on the availability of pools of human platelets that vary according to donors and blood centers. There is still no satisfactory standardization of these assays. DESIGN AND METHODS Peptide aptamer was used to detect and identify HPA-1a-specific antibodies in human serum that do not require human platelets. A peptide aptamer library was screened using an anti-HPA-1a human monoclonal antibody as a bait to isolate an aptamer that mimics the human platelet antigen HPA-1a. RESULTS This is the first report in platelet immunology of the use of a peptide aptamer for diagnostic purposes. This assay gives better results than the MAIPA currently in use, detecting around 90% of the expected alloantibodies. CONCLUSIONS This assay could help define a standard for the quantitation of anti-HPA antibodies. This report also demonstrates that peptide aptamers can potentially detect a variety of biomarkers in body fluids; this is of particular interest for diagnostic purposes.
Collapse
Affiliation(s)
- Julien Thibaut
- Université de Lyon, IBCP, UMR 5086 CNRS-Université Lyon, Lyon, France
| | | | | | | |
Collapse
|
21
|
Abstract
The pattern of autoimmune hemolytic anemia has changed significantly these last 15 years. With regard to the diagnosis strategy, the use of gel filtration technique to perform the direct antiglobulin test (DAT) has decreased the number of autoimmune haemolytic anemias with negative tests results. In recent years, autoimmune haemolytic anemia increased in patients receiving purine nucleoside analogues, blood transfusions, solid organ transplantation or hematopoietic stem cells transplantation. These difficult autoimmune haemolytic anemia cases need to use new kinds of treatments. With regard to the treatment, very little progress was made this latter 50 years. The discovery of the efficacy of anti-CD20 antibody in this disease represents a breakthrough. Nowdays, the second-line treatment includes rituximab or splenectomy. Sometimes, the anti-CD20 treatment could be proposed in first-line but some clinical trials are needed.
Collapse
Affiliation(s)
- D Rigal
- Laboratoire d'immunohématologie et service d'hémovigilance, établissement français du sang, 1-3, rue du Vercors, 69007 Lyon, France.
| | | |
Collapse
|
22
|
Domenech C, Thomas X, Chabaud S, Baruchel A, Gueyffier F, Mazingue F, Auvrignon A, Corm S, Dombret H, Chevallier P, Galambrun C, Huguet F, Legrand F, Mechinaud F, Vey N, Philip I, Liens D, Godfrin Y, Rigal D, Bertrand Y. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol 2011; 153:58-65. [PMID: 21332712 DOI: 10.1111/j.1365-2141.2011.08588.x] [Citation(s) in RCA: 106] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
l-asparaginase encapsulated within erythrocytes (GRASPA(®) ) should allow serum asparagine depletion over a longer period than the native form of the enzyme, using lower doses and allowing better tolerance. The GRASPALL 2005-01 study, a multicentre randomized controlled trial, investigated three doses of GRASPA(®) for the duration of asparagine depletion in a phase I/II study in adults and children with acute lymphoblastic leukaemia (ALL) in first relapse. Between February 2006 and April 2008, 18 patients received GRASPA(®) (50 iu/kg: n = 6,100 iu/kg: n = 6, 150 iu/kg: n = 6) after randomization, and six patients were assigned to the Escherichia coli native l-asparaginase (E. colil-ASNase) control group. GRASPA(®) was effective at depleting l-asparagine. One single injection of 150 iu/kg of GRASPA(®) provided similar results to 8 × 10,000 iu/m(2) intravenous injections of E. colil-ASNase. The safety profile of GRASPA(®) showed a reduction in the number and severity of allergic reactions and a trend towards less coagulation disorders. Other expected adverse events were comparable to those observed with E. colil-ASNase and there was also no difference between the three doses of GRASPA(®) .
Collapse
Affiliation(s)
- Carine Domenech
- Institut d'Hemato-Oncologie pédiatrique, Hospices civils de Lyon, Université Claude Bernard, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Bachy E, Bernaud J, Roy P, Rigal D, Nicolini FE. Quantitative and functional analyses of CD4(+) CD25(+) FoxP3(+) regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate. Br J Haematol 2011; 153:139-43. [PMID: 21275952 DOI: 10.1111/j.1365-2141.2010.08453.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
24
|
Michaud M, Barakat S, Magnard S, Rigal D, Baggetto LG. Leucine-rich protein 130 contributes to apoptosis resistance of human hepatocarcinoma cells. Int J Oncol 2011; 38:169-178. [PMID: 21109938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023] Open
Abstract
LRP130 is a ubiquitous protein involved in cellular homeostasis, microtubule alteration, and transactivation of a few multidrug resistance genes. Its role in resistance to apoptosis in HepG2 and HUH7 hepatocarcinoma cells was investigated. Using shRNA-producing lentiviruses to down-regulate the LRP130 gene, we showed that i) LRP130 did not affect the capacity of hepatocarcinoma cells to extrude drugs since LRP130 down-regulation was insufficient to significantly reduce P-glycoprotein production in these cells, and ii) the expression of 11 apoptosis-related genes measured by PCR-array was significantly reduced. Interestingly, six of these genes encode extrinsic pathway proapoptotic proteins whose expression was higher in LRP130-non producing than in LRP130-producing HepG2 cells. Fluorescence microscopy confirmed this new anti-apoptotic role of LRP130, which is strengthened by a significantly reduced cytochrome c oxidase activity in LRP130-down-regulated hepatocarcinoma cells.
Collapse
MESH Headings
- Antibiotics, Antineoplastic/pharmacokinetics
- Antibiotics, Antineoplastic/pharmacology
- Apoptosis/drug effects
- Apoptosis/genetics
- Carcinoma, Hepatocellular/drug therapy
- Carcinoma, Hepatocellular/genetics
- Carcinoma, Hepatocellular/metabolism
- Carcinoma, Hepatocellular/pathology
- Cell Line, Tumor
- Daunorubicin/pharmacokinetics
- Daunorubicin/pharmacology
- Down-Regulation
- Drug Resistance, Neoplasm
- Genetic Vectors
- Hep G2 Cells
- Humans
- Lentivirus/genetics
- Liver Neoplasms/drug therapy
- Liver Neoplasms/genetics
- Liver Neoplasms/metabolism
- Liver Neoplasms/pathology
- Microscopy, Fluorescence
- Neoplasm Proteins/genetics
- Neoplasm Proteins/metabolism
- RNA Interference
- RNA, Small Interfering/administration & dosage
- RNA, Small Interfering/genetics
- Transfection
Collapse
Affiliation(s)
- Mickaël Michaud
- Institut de Biologie et Chimie des Protéines-UMR5086 CNRS UCBL, 7 Passage du Vercors, F-69367 Lyon Cedex 07, France
| | | | | | | | | |
Collapse
|
25
|
Desmet C, Le Goff GC, Brès JC, Rigal D, Blum LJ, Marquette CA. Multiplexed immunoassay for the rapid detection of anti-tumor-associated antigens antibodies. Analyst 2011; 136:2918-24. [PMID: 21666912 DOI: 10.1039/c1an15121e] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- C Desmet
- Equipe Génie Enzymatique, Membranes Biomimétiques et Assemblages Supramoléculaires, Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, Université Lyon 1-CNRS 5246 ICBMS, Villeurbanne Cedex, France
| | | | | | | | | | | |
Collapse
|
26
|
Le Goff GC, Desmet C, Brès JC, Rigal D, Blum LJ, Marquette CA. Multipurpose high-throughput filtering microarrays (HiFi) for DNA and protein assays. Biosens Bioelectron 2010; 26:1142-51. [DOI: 10.1016/j.bios.2010.06.057] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2010] [Revised: 06/21/2010] [Accepted: 06/28/2010] [Indexed: 10/19/2022]
|
27
|
Bourgeaux V, Hequet O, Campion Y, Delcambre G, Chevrier AM, Rigal D, Godfrin Y. Inositol hexaphosphate-loaded red blood cells prevent in vitro sickling. Transfusion 2010; 50:2176-84. [PMID: 20456710 DOI: 10.1111/j.1537-2995.2010.02663.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Hypoxia is a major cause of painful vaso-occlusive crisis in sickle cell disease (SCD). Simple transfusion and red blood cell (RBC) exchange are commonly used as preventive therapies whose aim is to dilute hemoglobin (Hb)S-containing RBCs (SS-RBCs) with normal RBCs (AA-RBCs) to prevent sickling. We hypothesized that the effectiveness of transfusion could be improved by the encapsulation of inositol hexaphosphate (IHP), an allosteric Hb effector, in transfused AA-RBCs. Indeed, apart from their diluting effect on SS-RBCs, IHP-loaded RBCs (IHP-RBCs) with increased oxygen release capacity could palliate in vivo oxygen deprivation and reduce sickling. STUDY DESIGN AND METHODS The study was designed to investigate the therapeutic effect of IHP-RBCs transfusion on in vitro sickling of SS-RBCs collected from 20 SCD patients. Patients' RBCs were diluted with various proportions of IHP-RBCs or AA-RBCs (processed or stored RBCs as controls). Resulting suspensions were subjected to deoxygenation followed by partial reoxygenation at 5% oxygen. Sickling was evaluated by microscopy. RESULTS Stored RBCs (50% dose) used to mimic simple transfusion exhibited a poor antisickling effect (5.6%) and a low response rate (65%). In contrast, IHP-RBCs treatment was seven times more effective resulting in 35% of sickling reduction and a 94% response rate. Sickling was inhibited in a dose-dependent manner: 9.9, 25.1, and 35.0% for IHP-RBCs in percentages of 10, 30, and 50%, respectively. CONCLUSION Our results indicate that IHP-RBCs prevent in vitro sickling and suggest that it could improve conventional transfusion therapy in terms of transfused volume, frequency, and efficacy.
Collapse
|
28
|
Affiliation(s)
- Gaelle C. Le Goff
- Equipe Génie Enzymatique, Membranes Biomimétiques et Assemblages Supramoléculaires, Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, CNRS 5246 ICBMS, Université Lyon 1, Bâtiment CPE, 43 bd du 11 novembre 1918, 69622 Villeurbanne Cedex, and Etablissement Français du Sang Rhône-Alpes, Lyon, France
| | - Jean-Charles Brès
- Equipe Génie Enzymatique, Membranes Biomimétiques et Assemblages Supramoléculaires, Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, CNRS 5246 ICBMS, Université Lyon 1, Bâtiment CPE, 43 bd du 11 novembre 1918, 69622 Villeurbanne Cedex, and Etablissement Français du Sang Rhône-Alpes, Lyon, France
| | - Dominique Rigal
- Equipe Génie Enzymatique, Membranes Biomimétiques et Assemblages Supramoléculaires, Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, CNRS 5246 ICBMS, Université Lyon 1, Bâtiment CPE, 43 bd du 11 novembre 1918, 69622 Villeurbanne Cedex, and Etablissement Français du Sang Rhône-Alpes, Lyon, France
| | - Loïc J. Blum
- Equipe Génie Enzymatique, Membranes Biomimétiques et Assemblages Supramoléculaires, Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, CNRS 5246 ICBMS, Université Lyon 1, Bâtiment CPE, 43 bd du 11 novembre 1918, 69622 Villeurbanne Cedex, and Etablissement Français du Sang Rhône-Alpes, Lyon, France
| | - Christophe A. Marquette
- Equipe Génie Enzymatique, Membranes Biomimétiques et Assemblages Supramoléculaires, Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, CNRS 5246 ICBMS, Université Lyon 1, Bâtiment CPE, 43 bd du 11 novembre 1918, 69622 Villeurbanne Cedex, and Etablissement Français du Sang Rhône-Alpes, Lyon, France
| |
Collapse
|
29
|
El Khoury G, Laurenceau E, Chevolot Y, Mérieux Y, Desbos A, Fabien N, Rigal D, Souteyrand E, Cloarec JP. Development of miniaturized immunoassay: Influence of surface chemistry and comparison with enzyme-linked immunosorbent assay and Western blot. Anal Biochem 2010; 400:10-8. [DOI: 10.1016/j.ab.2010.01.013] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2009] [Revised: 01/06/2010] [Accepted: 01/10/2010] [Indexed: 10/19/2022]
|
30
|
Hequet O, Le Q, Rigal D, Mekhloufi F, Jaeger S, Sassolas A, Groisne L, Moulin P. The first results demonstrating efficiency and safety of a double-column whole blood method of LDL-apheresis. Transfus Apher Sci 2010; 42:3-10. [DOI: 10.1016/j.transci.2009.10.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2008] [Accepted: 08/25/2009] [Indexed: 10/20/2022]
|
31
|
Moncharmont P, Buclet D, Trouilloud C, Peyrard T, Rigal D. Severe hemolytic disease of the fetus and the newborn associated with anti-Vw (Vw). J Matern Fetal Neonatal Med 2009; 23:1066-8. [DOI: 10.3109/14767050903366085] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
32
|
Moncharmont P, Ghesquieres H, Sebban C, Debourdeau P, Pavic M, Biron P, Rigal D. Severe IgA-mediated autoimmune haemolytic anaemia in Hodgkin lymphoma: A very rare event. Leuk Lymphoma 2009; 48:633-5. [PMID: 17454613 DOI: 10.1080/10428190601120357] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
33
|
Guillot-Chene P, Lebecque S, Rigal D. [Towards an industrial control of the cloning of lymphocytes B human for the manufacturing of monoclonal antibodies stemming from the human repertoire]. Ann Pharm Fr 2009; 67:182-6. [PMID: 19446667 DOI: 10.1016/j.pharma.2009.02.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2008] [Revised: 01/09/2009] [Accepted: 02/20/2009] [Indexed: 11/17/2022]
Abstract
Monoclonal antibodies (mAbs) are efficient drugs for treating infectious, inflammatory and cancer diseases. Antibodies secreted by human lymphocytes that have been isolated from either peripheral blood or tissues present the definite interest of being part of the physiological or disease-related response to antigens present in the human body. However, attempts to generate hybridomas with human B cells have been largely unsuccessful, and cloning of human B cells has been achieved only via their inefficient immortalization with Epstein Barr Virus (EBV). However, recent progress in our understanding of the molecular mechanisms of polyclonal B cell activation has dramatically increased the capacity to clone human B cells. In particular, activation of human naïve and memory B cells through CD40 or memory B cells only through TLR9 was shown to greatly facilitate their immortalization by EBV. Industrial development based on these observations will soon provide large collections of high affinity human mAbs of every isotype directly selected by the human immune system directed to recognize epitopes relevant for individual patients. Moreover, after CD40 activation, these mAbs will cover the full human repertoire, including the natural auto-immune repertoire. Full characterization of the biological activity of these mAbs will in turn bring useful information for selecting vaccine epitopes. This breakthrough in human B cell cloning opens the way into new areas for therapeutic use of mAbs.
Collapse
|
34
|
Abstract
In Evans syndrome, IgG auto-antibodies (Abs) and/or complement components are frequently detected on red blood cells (RBC) in the direct antiglobulin test (DAT). A 70-year-old man with Evans syndrome diagnosed four years previously presented with a persistent autoimmune haemolytic anaemia, despite immunosuppressive treatment and normalization of platelet count. The RBC allo- and auto-Abs screening and identification were performed by indirect antiglobulin test (IAT) and DAT. In March 2006, no circulating anti-RBC auto-Abs were found in IAT but the DAT was positive with anti-IgG (++), -C3d (weak) and -IgA (++). Follow up for 11 months revealed anti-RBC IgA auto-Abs on five out of six samples. IAT was positive for RBC auto-Abs on three samples. No correlation between the haemoglobin level and the strength of reactivity of IgG and IgA auto-Abs was observed. IgA anti-RBC auto-Abs are present in Evans syndrome. To detect these Abs and characterize their role, DAT procedures should systematically include anti-IgA.
Collapse
Affiliation(s)
- P Moncharmont
- Etablissement français du Sang - Rhône-Alpes, Site de Lyon, Lyon Cedex 07, France.
| | | | | |
Collapse
|
35
|
|
36
|
Lech-Maranda E, Baseggio L, Charlot C, Rigal D, Berger F, Jamroziak K, Warzocha K, Coiffier B, Salles G. Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. Leuk Lymphoma 2008; 48:2235-8. [PMID: 17990180 DOI: 10.1080/10428190701615926] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
37
|
Gillet-Hladky S, Duperrier K, Picandet S, Mathias V, de Carvalho MC, Bernaud J, Masseau D, Bienvenu J, Rigal D. Induction of high expression of CCR7 and high production of IL-12 in human monocyte-derived dendritic cells by a new bacterial component: LCOS 1013. Int Immunopharmacol 2008; 8:1151-63. [PMID: 18602060 DOI: 10.1016/j.intimp.2008.02.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2006] [Revised: 12/19/2007] [Accepted: 02/18/2008] [Indexed: 01/10/2023]
Abstract
Dendritic cells (DCs) are the most potent antigen presenting cells of the immune system as they can act as initiators, stimulators and regulators of the immune response. Human DCs are most commonly generated for clinical use by in vitro differentiation of monocytes with exogenous cytokines. Here, we investigate the effect of LCOS 1013 on the production of mature Mo-DCs. LCOS 1013 is a new bacterial component from walls of gram(+)Klebsellia pneumoniae bacteria that contain some OmpA glycoproteins. Purified peripheral blood monocytes were cultured for 6 days with IL-4 and GM-CSF in order to obtain immature dendritic cells (Im-MoDCs). On day six, Im-MoDCs were matured with either LCOS 1013, TNF alpha, LPS or CD40-Ligand. LCOS 1013 matured Mo-DCs (LCO-DCs) showed a higher expression of DC-LAMP, CD80, CD83, CD54 and CD40 than TNF alpha, LPS and CD40L matured Mo-DCs. Interestingly, LCO-DCs exhibited high expression of full competent CCR7 and high secretion of IL-12 during their maturation. Functionally, LCO-DCs have equivalent potency to trigger mixed leukocyte reaction and antigen-specific reaction and polarize immune response towards Th1 way. Moreover, we found that LCOS 1013 activates DCs through TLR2. LCOS 1013 represents an attractive therapeutic maturation agent of DCs allowing the production of Mo-DCs with high capacity to migrate and to induced Th1 immune responses.
Collapse
|
38
|
El Khoury G, Laurenceau E, Dugas V, Chevolot Y, Mérieux Y, Duclos MC, Souteyrand E, Rigal D, Wallach J, Cloarec JP. Acid deprotection of covalently immobilized peptide probes on glass slides for peptide microarrays. ACTA ACUST UNITED AC 2007; 2007:2242-6. [PMID: 18002437 DOI: 10.1109/iembs.2007.4352771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Protein microarray technology has shown great advancements in the field of biomedical research and diagnosis, it allows to study and understand protein activities and protein - ligand interactions (e.g. detection of antigen-autoantibody interaction in autoimmune diseases. Autoantibodies are frequently targeted against antigens of the cell nucleus (double and single stranded DNA, histones, and nuclear antigens). The biological activities of proteins (e.g. enzymes, antibodies...) are controlled by peptides sequences of the active site. Consequently, we were interested in the investigation of peptide microarrays in order to further implement in situ peptide synthesis, in particular, deprotection reaction on glass supported peptides. In this work, a protected and biotinylated synthetic peptide was covalently immobilized onto amino functionalized glass surface by activation of its the C-terminus; this allows to orientate the peptide onto the surface. The peptide contains a fragment of the C-terminal end of the human histone H3 protein. The immobilized peptide was then deprotected by using concentrated trifluoroacetic acid solution. After the deprotection, surface stability and peptide grafting density were evaluated by indirect labelling of the immobilized peptide using Cy3 streptavidin conjugates. We also studied biological interaction of IgG polyclonal anti-histone H3 antibody with the immobilized peptide epitope to insure the efficiency of the acid deprotection. The specificity of the antibody interaction with the protected versus non protected peptides. This approach may be applied to in situ synthetic and prototected peptides, in order to elaborate a micro-immunoassay prototype for measurement of peptide-protein interactions on high density microarrays, and detection of antibodies in biological fluids such as serum.
Collapse
|
39
|
Foxcroft Z, Campbell K, Merieux Y, Urbaniak S, Brierley M, Rigal D, Ouwehand WH, Metcalfe P. Report on the 13th International Society of Blood Transfusion Platelet Immunology Workshop. Vox Sang 2007; 93:300-5. [PMID: 18070273 DOI: 10.1111/j.1423-0410.2007.00951.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND OBJECTIVES The aim of the 13th International Society of Blood Transfusion Platelet Immunology Workshop was to compare the sensitivity and specificity of the in-house method for the detection of human platelet antigen (HPA) antibodies currently used in participating laboratories with a modified rapid protocol for the monoclonal antibody (mAb) immobilization of platelet antigen (MR-MAIPA) assay. MATERIALS AND METHODS Twenty-eight laboratories from 15 countries participated. A set of four freeze-dried minimum potency reference reagents with known single-specificity HPA antibodies were supplied for testing by titration with both assays and two coded freeze-dried plasma samples were provided for antibody specificity testing. Critical reagents and materials for the MR-MAIPA were provided including lyophilized panel platelets and five capture mAbs. RESULTS Titration of the reference standards showed that the sensitivity of the MR-MAIPA was the same as the in-house methods. The proposed replacement anti-HPA-1a reference reagent 05/106 gave results that did not differ significantly from the current reference reagent 93/710. The results with the two blinded samples showed that in the first sample, 27 out of the 28 laboratories were able to correctly identify the anti-HPA-1a present when using their respective in-house methods, but only 23 correctly identified the antibody when using the rapid MAIPA method. The results from the second sample, which contained multispecificities, showed that only 50% of the participants correctly identified all five antibodies present using their in-house method. The results for the rapid MAIPA were lower, with only 32% identifying all specificities. The variability in the reconstitution of the freeze-dried platelets may have been one of the contributing factors to the poorer results. CONCLUSIONS The sensitivity of the MR-MAIPA compared favourably with that of the in-house methods. Most laboratories were able to identify anti-HPA-1a alone in Sample 1 but more than half of the participants were not able to correctly assign the specificity of all HPA antibodies present in the second sample. The usefulness of the panel of freeze-dried platelets varied considerably between laboratories.
Collapse
Affiliation(s)
- Z Foxcroft
- South African National Blood Service, Johannesburg, South Africa.
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
UNLABELLED The HPA-15 platelet (PLT) group was recently described. Severe neonatal thrombocytopenia due to alloimmunization by HPA-15b has very rarely been observed. A 22-year-old mother, gravida 1/para 1, gave birth to a male infant who presented with a severe thrombocytopenia, the PLT count recorded to be 3 x10(9)/L. A few hours after birth, he developed purpura with extensive haematomas but without visceral or intracranial haemorrhage (ICH). Two PLT transfusions were given including one using maternal PLTs. The infant's PLT count was 267 x 10(9)/L on day 6. The maternal platelet group was HPA-15a/a and her infant was HPA-15a/b. Anti-HPA-15b antibodies was found in maternal serum. CONCLUSION HPA-15b maternal alloimmunization may induce severe neonatal thrombocytopenia. In order to establish the frequency of neonatal alloimmune thrombocytopenia (NAIT) due to anti-HPA-15b antibodies, an improved detection method is necessary.
Collapse
MESH Headings
- Adult
- Antigens, CD/blood
- Antigens, CD/immunology
- Antigens, Human Platelet/blood
- Antigens, Human Platelet/immunology
- Blood Group Incompatibility/complications
- Blood Group Incompatibility/diagnosis
- Blood Group Incompatibility/therapy
- Cesarean Section
- Female
- GPI-Linked Proteins
- Humans
- Infant, Newborn
- Male
- Maternal-Fetal Exchange/immunology
- Neoplasm Proteins/blood
- Neoplasm Proteins/immunology
- Platelet Transfusion
- Pregnancy
- Pregnancy Complications, Hematologic/immunology
- Purpura, Thrombocytopenic/etiology
- Thrombocytopenia, Neonatal Alloimmune/diagnosis
- Thrombocytopenia, Neonatal Alloimmune/immunology
- Thrombocytopenia, Neonatal Alloimmune/therapy
Collapse
Affiliation(s)
- P Moncharmont
- French Blood Establishment, Rhône-Alpes Lyon Department, Lyon, France.
| | | | | | | | | | | |
Collapse
|
41
|
Porra V, Bernaud J, Gueret P, Bricca P, Rigal D, Follea G, Blanchard D. Identification and quantification of fetal red blood cells in maternal blood by a dual-color flow cytometric method: evaluation of the Fetal Cell Count kit. Transfusion 2007; 47:1281-9. [PMID: 17581165 DOI: 10.1111/j.1537-2995.2007.01271.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND As an alternative to the cumbersome Kleihauer-Betke test (KBT), flow cytometry represents a powerful method for the identification and quantification of fetal red blood cells (RBCs) in maternal circulation. STUDY DESIGN AND METHODS The aim of this study was to evaluate the Fetal Cell Count kit (IQ Products), an innovative flow cytometric method, based on the combination of antibodies directed, respectively, against fetal hemoglobin (HbF) and carbonic anhydrase (CA), a marker expressed after birth, to discriminate fetal RBCs from adult F cells containing HbF. The investigation was performed by two French laboratories that compared the data obtained by flow cytometry and KBT in 455 pregnant or just-delivered women as well as in 124 artificial mixtures containing from 0.01 to 5.00 percent cord cells. RESULTS The FL1/FL2 histogram allowed distinction between fetal RBCs (HbF+, CA-), F cells (HbF+, CA+), and adult RBCs (HbF-, CA+). The limits of detection and quantification were determined at 0.03 and 0.10 percent or 0.02 and 0.05 percent when analyzing 100,000 or 200,000 events, respectively. Linearity was demonstrated between 0.01 and 5.00 percent fetal cells in the mixtures (r = 0.95, p < 0.01). A good correlation between fluorescence-activated cell sorting (FACS) and KBT results was obtained with artificial mixtures (r = 0.94, p < 0.01). From the 405 Kleihauer-negative samples, none were identified as positive by FACS. Among the 50 Kleihauer-positive samples, 6 were shown not to contain fetal cells but F cells by FACS. CONCLUSION With this new dual-color flow cytometric method, accurate evaluation of fetomaternal hemorrhage was achieved even in the face of HbF of maternal origin.
Collapse
|
42
|
Bonnefont-Rebeix C, Marchal T, Bernaud J, Pin JJ, Leroux C, Lebecque S, Chabanne L, Rigal D. Toll-like receptor 3 (TLR3): A new marker of canine monocytes-derived dendritic cells (cMo-DC). Vet Immunol Immunopathol 2007; 118:134-9. [PMID: 17521746 DOI: 10.1016/j.vetimm.2007.04.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2006] [Revised: 03/28/2007] [Accepted: 04/12/2007] [Indexed: 11/28/2022]
Abstract
Toll-like receptors (TLRs) are a family of functionally important receptors for recognition of pathogen-associated molecular pattern (PAMP) since they trigger the pro-inflammatory response and upregulation of costimulatory molecules, linking the rapid innate response to adaptative immunity. In human leukocytes, TLR3 has been found to be specifically expressed in dendritic cells (DC). This study examined the expression of TLR3 in canine monocytes-derived DC (cMo-DC) and PBMC using three new anti-TLR3 mAbs (619F7, 722E2 and 713E4 clones). The non-adherent cMo-DC generated after culture in canine IL-4 plus canine GM-CSF were labelled with the three anti-TLR3 clones by flow cytometry, with a strong expression shown for 619F7 and 722E2 clones. By contrast, TLR3 expression was low to moderate in canine monocytes and lymphocytes. These results were confirmed by Western blot using 619F7 and 722E2 clones and several polypeptide bands were observed, suggesting a possible cleavage of TLR3 molecule or different glycosylation states. In addition, TLR3 was detectable in immunocytochemistry by using 722E2 clone. In conclusion, this first approach to study canine TLR3 protein expression shows that three anti-TLR3 clones detect canine TLR3 and can be used to better characterize canine DC and the immune system of dogs.
Collapse
|
43
|
Moncharmont P, Vignal M, Merieux Y, Rigal D. [Intravenous human immunoglobulin treatment for neonatal alloimmune thrombocytopenia due to anti-HPA-5b with severe previous history]. Arch Pediatr 2007; 14:1094-6. [PMID: 17590318 DOI: 10.1016/j.arcped.2007.05.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2006] [Accepted: 05/11/2007] [Indexed: 10/23/2022]
Abstract
Fetal and neonatal alloimmune thrombocytopenia due to mothers' anti-HPA-5b alloimmunization has generally a milder clinical presentation compared to anti-HPA-1a alloimmunization. Nevertheless, a case with infant's death probably due to intracranial haemorrhage has been reported. However, if platelet-specific alloimmunized mothers with prior fetal or neonate injury receive intravenous immunoglobulins during pregnancy, thrombocytopenia in heterozygous fetus and neonate may be prevented. Here are reported 2 cases of anti-HPA-5b fetal-maternal alloimmunization, one with prior fetal death, the other with prior severe fetal intracranial haemorrhage, which were successfully treated with intraveinous immunoglobulins alone during a second pregnancy with HPA-5b incompatibility.
Collapse
Affiliation(s)
- P Moncharmont
- Etablissement français du sang, Rhône-Alpes, site de Lyon-Gerland, 1-3, rue du Vercors, 69364 Lyon cedex 07, France.
| | | | | | | |
Collapse
|
44
|
Hequet O, Lienhart A, Jaeger S, Meunier S, Sobas F, Rigal D, Negrier C. Adaptability of protein A-immunoadsorption allows temporary reduction of anti-VIII antibodies and realisation of high-risk haemorrhagic surgery. Transfus Apher Sci 2007; 36:255-8. [PMID: 17569589 DOI: 10.1016/j.transci.2007.04.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
We report the successful treatment by protein A-immunoadsorption (IA) of an hemophilic man with anti-F VIII antibodies (Abs) who needed high-risk bleeding surgery. This patient had developed high levels of anti-F VIII Abs preventing substitution by clotting factor and preventing high-risk bleeding surgery. Because of rebound in Abs levels or complications, IA procedures were modified several times leading to appropriate decrease of anti-F VIII inhibitor Abs allowing bilateral knees surgery. IA procedure is enough adaptable to be modified to prevent complications. Collaboration between clinical, biological, apheresis and surgical teams implied has permitted surgery and prevented life-threatening bleeding complications.
Collapse
Affiliation(s)
- O Hequet
- Centre de Santé, Etablissement Français du Sang, Hôpital Edouard Herriot, Lyon, France.
| | | | | | | | | | | | | |
Collapse
|
45
|
Cao WH, Wang X, Frappart L, Rigal D, Wang ZQ, Shen Y, Tong WM. Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients. Mutat Res 2007; 632:20-8. [PMID: 17560163 DOI: 10.1016/j.mrgentox.2007.04.011] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2006] [Revised: 03/20/2007] [Accepted: 04/03/2007] [Indexed: 11/23/2022]
Abstract
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that catalyzes the poly(ADP-ribosyl)ation of target proteins in response to DNA damage and has been proposed to play a role in DNA repair, recombination, transcription, cell death, cell proliferation, as well as in stabilization of the genome. We have recently shown that PARP-1 deficiency causes mammary tumorigenesis in mice. In the present study, we investigated whether genetic variants and single nucleotide polymorphisms (SNPs) of PARP-1 contribute to human breast cancer. To this end, we screened all PARP-1 exons, 7.1kb of intron-exon junction and 1.0-kb promoter sequences in 83 French patients with breast cancer and 100 controls by direct sequencing of genomic DNA. Twenty rare genetic variants of PARP-1, including c.1148C>A (Ser383Tyr), c.1354C>A (Arg452Arg), c.2819A>G (Lys940Arg) were detected in nine (10.8%) breast cancers of these patients. Among 31 polymorphic sites examined, five haplotype-tagging SNPs (htSNPs) of PARP-1 were identified. Interestingly, the genotype distribution of htSNP c.852T>C (Ala284Ala) was likely associated with loss of estrogen- and progesterone-receptor expression. The present study implies that genetic variants of PARP-1 may contribute to breast cancerogenesis and that PARP-1 htSNP c.852T>C (Ala284Ala) may influence hormonal therapy of breast cancer.
Collapse
Affiliation(s)
- Wen-Hui Cao
- National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, 5, Dong Dan San Tiao, Beijing 100005, China
| | | | | | | | | | | | | |
Collapse
|
46
|
Moncharmont P, Vignal M, Merieux Y, Rigal D. Delayed severe HPA-5b neonatal alloimmune thrombocytopenia: a case report. J Matern Fetal Neonatal Med 2007; 20:75-6. [PMID: 17437204 DOI: 10.1080/14767050601128134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
47
|
Bonnin N, Viennet A, Nezzar H, Dechelotte P, Barthelemy I, Demeocq F, Gabrillargues J, Campagne D, Rigal D, Bacin F. 448 Rhabdomyosarcome palpébral chez un enfant de deux ans. J Fr Ophtalmol 2007. [DOI: 10.1016/s0181-5512(07)80261-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
48
|
Albertini E, Iraci A, Coulangeon L, Creveaux I, Rigal D, Chiambaretta F. 519 Dystrophie grillagée chez l’enfant : une expression phénotypique évolutive. J Fr Ophtalmol 2007. [DOI: 10.1016/s0181-5512(07)80332-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
49
|
Laurin D, Spierings E, van der Veken LT, Hamrouni A, Falkenburg JHF, Souillet G, Vermeulen C, Farre A, Galambrun C, Rigal D, Bertrand Y, Goulmy E, Eljaafari A. Minor histocompatibility antigen DDX3Y induces HLA-DQ5-restricted T cell responses with limited TCR-Vbeta usage both in vivo and in vitro. Biol Blood Marrow Transplant 2007; 12:1114-24. [PMID: 17085304 DOI: 10.1016/j.bbmt.2006.07.012] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2006] [Accepted: 07/20/2006] [Indexed: 11/24/2022]
Abstract
In vitro stimulation of human female T cells with male HLA-identical dendritic cells resulted in the generation of HLA-DQB1*0501/0502-restricted minor histocompatibility H-Y antigen-specific CD4(+) T cell clones. Two clones generated from different HLA-identical pairs were analyzed. Use of HLA-DQ5-expressing female Epstein-Barr virus transformed B lymphoblastoid cell lines transfected with various H-Y genes and loaded with overlapping peptides demonstrated that both T cell clones are specific for a peptide encoded by DDX3Y. Previously, an HLA-DQ5-restricted T cell clone specific for the same peptide was isolated from a patient with graft-versus-host disease. Thus, we compared the T cell receptor (TCR) rearrangements of the 2 in vitro generated T cell clones and the ex vivo isolated T cell clone. All 3 clones shared the same TCRBV5-4* gene segment and 2 of 3 clones also used similar TCR-Valpha segments. Our results suggest that T cells recognizing the HLA-DQ5/DDX3Y T cell epitope might be characterized by a relatively limited TCR-beta repertoire. The differences in the junctional TCR-beta region had no effect on the antigen specificity, but altered the capacity of the TCR to distinguish the HLA-DQ5/DDX3Y complex from its allelic counterpart. The results also demonstrate that in vitro stimulation of T cells with allogeneic HLA-identical dendritic cells may facilitate the characterization of in vivo, potentially relevant HLA class II-restricted minor H epitopes.
Collapse
Affiliation(s)
- David Laurin
- Cell Therapy Department, Etablissement Français du Sang Région Rhône-Alpes, Rhône, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Gillet-Hladky S, de Carvalho CM, Bernaud J, Bendahou C, Bloy C, Rigal D. Rabbit antithymocyte globulin inhibits monocyte-derived dendritic cells maturation in vitro and polarizes monocyte-derived dendritic cells towards tolerogenic dendritic cells expressing indoleamine 2,3-dioxygenase. Transplantation 2006; 82:965-74. [PMID: 17038913 DOI: 10.1097/01.tp.0000235549.47976.d0] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND Rabbit antithymocyte globulin (rATG) is a polyclonal mixture of immunoglobulin (Ig) G. It is used to prevent graft rejection and also graft versus host disease after transplantation. Its effect on lymphocyte function has been widely studied. Dendritic cells are central actors of the immune system. As antigen presenting cells, they are able to initiate, stimulate, and modulate immune responses. METHODS In this study, we investigated rATG effects on in vitro differentiation and maturation of monocyte-derived dendritic cells (Mo-DCs). RESULTS rATG inhibited maturation of immature Mo-DCs and allowed the generation of dendritic cells expressing ILT-3, CD123, CCR6 but not CCR7 and producing Indoleamine 2,3-dioxygenase mRNA as well as interferon-alpha. CONCLUSION rATG polarizes in vitro Mo-DCs towards tolerogenic dendritic cells.
Collapse
|